JP2025536416A - 置換ピペラジン誘導体の結晶およびその調製方法 - Google Patents

置換ピペラジン誘導体の結晶およびその調製方法

Info

Publication number
JP2025536416A
JP2025536416A JP2025525056A JP2025525056A JP2025536416A JP 2025536416 A JP2025536416 A JP 2025536416A JP 2025525056 A JP2025525056 A JP 2025525056A JP 2025525056 A JP2025525056 A JP 2025525056A JP 2025536416 A JP2025536416 A JP 2025536416A
Authority
JP
Japan
Prior art keywords
crystalline form
crystal
diffraction pattern
solvent
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025525056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025536416A5 (https=
Inventor
劉兆軍
楚洪柱
朱▲ユウ▼沁
曹▲シン▼
魏用剛
孫毅
Original Assignee
康百達（四川）生物医薬科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 康百達（四川）生物医薬科技有限公司 filed Critical 康百達（四川）生物医薬科技有限公司
Publication of JP2025536416A publication Critical patent/JP2025536416A/ja
Publication of JP2025536416A5 publication Critical patent/JP2025536416A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2025525056A 2022-11-14 2023-11-14 置換ピペラジン誘導体の結晶およびその調製方法 Pending JP2025536416A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211417721 2022-11-14
CN202211417721.3 2022-11-14
PCT/CN2023/131627 WO2024104354A1 (zh) 2022-11-14 2023-11-14 一种取代的哌嗪衍生物的晶体及其制备方法

Publications (2)

Publication Number Publication Date
JP2025536416A true JP2025536416A (ja) 2025-11-05
JP2025536416A5 JP2025536416A5 (https=) 2026-04-10

Family

ID=90997576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025525056A Pending JP2025536416A (ja) 2022-11-14 2023-11-14 置換ピペラジン誘導体の結晶およびその調製方法

Country Status (9)

Country Link
US (1) US20250270223A1 (https=)
EP (1) EP4620958A1 (https=)
JP (1) JP2025536416A (https=)
KR (1) KR20250086779A (https=)
CN (1) CN118027039A (https=)
AU (1) AU2023381502A1 (https=)
MX (1) MX2025005591A (https=)
TW (1) TWI879228B (https=)
WO (1) WO2024104354A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202508597A (zh) * 2023-08-17 2025-03-01 大陸商康百達（四川）生物醫藥科技有限公司 一種呱嗪衍生物的藥物製劑、其製備方法及其用途
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN112424188A (zh) * 2018-04-30 2021-02-26 里邦医疗公司 作为parp7抑制剂的哒嗪酮
CN112745312A (zh) * 2019-10-30 2021-05-04 沈阳中化农药化工研发有限公司 哒嗪酮异恶唑甲醚类化合物及其应用
WO2021087018A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
WO2022111700A1 (zh) * 2020-11-27 2022-06-02 成都百裕制药股份有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
WO2022242750A1 (zh) * 2021-05-21 2022-11-24 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112424188A (zh) * 2018-04-30 2021-02-26 里邦医疗公司 作为parp7抑制剂的哒嗪酮
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN112745312A (zh) * 2019-10-30 2021-05-04 沈阳中化农药化工研发有限公司 哒嗪酮异恶唑甲醚类化合物及其应用
WO2021087018A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
WO2022111700A1 (zh) * 2020-11-27 2022-06-02 成都百裕制药股份有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
WO2022242750A1 (zh) * 2021-05-21 2022-11-24 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用

Also Published As

Publication number Publication date
CN118027039A (zh) 2024-05-14
TW202426452A (zh) 2024-07-01
WO2024104354A1 (zh) 2024-05-23
MX2025005591A (es) 2025-06-02
TWI879228B (zh) 2025-04-01
AU2023381502A1 (en) 2025-05-15
EP4620958A1 (en) 2025-09-24
US20250270223A1 (en) 2025-08-28
KR20250086779A (ko) 2025-06-13

Similar Documents

Publication Publication Date Title
JP6131384B2 (ja) 重水素化ジアミノピリミジン化合物およびこの化合物を含む薬物組成物
KR102081042B1 (ko) 상피 성장 인자 수용체 키나제 억제제의 고체 형태
CN113544128A (zh) Kras-g12c抑制剂
JP6317320B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
JP2023522012A (ja) 結晶ｒｅｔ阻害剤
US20250270223A1 (en) Crystal of substituted piperazine derivative and preparation method therefor
KR20180032680A (ko) 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
CN101094853A (zh) 可用作蛋白激酶抑制剂的吡唑并[1,5－a]嘧啶
AU2018226922B2 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
JP6894917B2 (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
CN114853672B (zh) 作为CDKs抑制剂的他克林衍生物及其应用
JP7778750B2 (ja) ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
TW201629060A (zh) 一種週期素依賴性蛋白激酶抑制劑的羥乙基磺酸鹽、其結晶形式及製備方法
KR20220020951A (ko) Cdk 키나제 억제제
CA3093323C (en) Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
CN118632843A (zh) 一种吡啶类衍生物及其用途
CN113880804A (zh) 新型苯并咪唑化合物
WO2023137420A1 (en) Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1h-indole-7-carbonitrile
JP7618575B2 (ja) Ｎ－（５－（（４－エチルピペラジン－１－イル）メチル）ピリジン－２－イル）－５－フルオロ－４－（３－イソプロピル－２－メチル－２ｈ－インダゾール－５－イル）ピリミジン－２－アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
HK40104801A (zh) 一种取代的哌嗪衍生物的晶体及其制备方法
TWI919884B (zh) 一種嘧啶并氮雜環類化合物的晶型及其製備方法及應用
WO2025223554A1 (zh) 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用
TW202327593A (zh) Kras抑制劑的多晶型物及其製備方法和用途
EP4036086A1 (en) Heterocyclic derivative and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260402

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260421